All News
Low Risk of Malignancy with Secukinumab
Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).
Read Article
DMARD Dropouts During COVID-19
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.
Read Article
Thanks @uptoTate for sharing this great quote from #RNL2021
"Dactylitis to me is enthesitis and synovitis in the same digit." Dr. A. Kavanaugh #RNL2021"
Dr. John Cush RheumNow ( View Tweet)
Did you get a chance to listen to last week's podcast?#RheumNow
Mistakes with Steroids
https://t.co/qHtiyTzQme https://t.co/RI5XnZOmV2
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: GLP-1 Therapy in Knee Osteoarthritis
Knee osteoarthritis (KOA) is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable.
https://t.co/0YB5rOuJiD #RheumNow https://t.co/LEFUBTlJq4
Links:
Dr. John Cush RheumNow ( View Tweet)
Med nonadherence is universal 1) at 1 yr, only 48% pts still take their statins, 2) 1 in 4 pregnant asthmatics dont take their inhaled corticosteroids,. 3) half of psychiatric pts don’t take their psychotropic meds. What are the reasons for noncompliance? https://t.co/OBAfbFLIO9
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 26 patients with chronic inflammatory cdiseases vaccinated with mRNA vaccines showed all with considerable immunogenic responses. No unexpected side effects seen and No flares of the underlying inflammatory disease was seen. https://t.co/7Q5bYp5A9i
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Overview of New VEXAS Syndrome
Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health.
https://t.co/9oDtahJ9yI #RheumNow https://t.co/5yBiiRPWb3
Links:
Dr. John Cush RheumNow ( View Tweet)
RT from @KDAO2011"When Ustekinumab was developed, it was accidental that the p40 subunit targeted blocked both IL-12 and IL-23 (original intent to block only IL23) blocking I12 may decrease response to IL-23. this drug is better for skin than for joints - Dr. E Ruderman #RNL2021
Dr. John Cush RheumNow ( View Tweet)
News Feature: Can Targeting RANKL in RA Heal Erosions?
Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.
https://t.co/kpYozqR8vD #RheumNow https://t.co/m0SjJzfp8m
Links:
Dr. John Cush RheumNow ( View Tweet)
RT from @doctorRBC covering #RNL2021
--------
Make sure to screen your PsO and PsA for depression and mental health. Worsening depression can cause emotional stress, leading to worse disease. #RNL2021
#rheumnow
Dr. John Cush RheumNow ( View Tweet)
News Feature: Implementing Smoking Cessation Programs #RheumNow
https://t.co/wEBZRd3n8Q https://t.co/c5yfIyl2Vc
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 Tweet from @uptoTate
2020 (contact) allergen of the year: Essential Oils! Keep on using 'em in order to put your family-friendly dermatologist's kids through school! Melodie Young, NP #RNL2021
Dr. John Cush RheumNow ( View Tweet)
11 RCTs (4,329 pts) & 19 registries (9,739 pts) studied Rx efficacy in CTD pts w/ pulmonary HTN. Overall, Rx (Sildenafil, Treprostinil, Bosentan, etc) reduced mortality 36% vs controls. CTD‐PAH survival was lower (52% v 72%) vs PAH; higher after 2010 https://t.co/IFb3nLiJbL
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available--Mistakes with Steroids
Dr Jack Cush gives his spin on this week's news featured on RheumNow.
Download wherever podcasts are available.
https://t.co/cUI65I9759 https://t.co/fOWJXW50nI
Links:
Dr. John Cush RheumNow ( View Tweet)
HLA-B27 status does not change the risk of COVID-19 in spondyloarthritis patients. Survey of 3435 SpA pts; shows 76% as HLA-B27 positive. COVID infx was thesame between B27 Pos & Neg pts (1.5% vs 1.4%) and severity was also the same https://t.co/qavodFynr0
Links:
Dr. John Cush RheumNow ( View Tweet)
Axial Involvement in SpA: A Patient-Centered Exploration
Sponsored by Novartis Medical Affairs
Listen to Ethan Craig, MD, MPH present insights from patient cases to distinguish axial involvement within the spectrum of SpA.
https://t.co/o2q5pTP3WD https://t.co/IXHs0LHSOe
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from @DrPetryna
Refractory RA by Dr. Buch:
-active DZ after >2 b/ts DMARDs
-why rfRA exists:
?Immunologic heterogeneity of RA
?contributing co-morbidities
?unidentified Rx target
-effective Rx in early disease decreases risk of future rfRA" https://t.co/ecrbqlvemf
Dr. John Cush RheumNow ( View Tweet)
News Feature: Rheumatology Care Derailed by COVID-19
A survey study from the ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.
https://t.co/BqY0vJpdm8 https://t.co/nZcuL4FbEw
Links:
Dr. John Cush RheumNow ( View Tweet)
Don’t underestimate the utility of Vitamin D for VTE ppx in APS patients. Everyone should get some sun
#RNL2021 Coverage from @doctorRBC #RheumNow
Dr. John Cush RheumNow ( View Tweet)